Search hospitals > Montana > Billings
St. Vincent Healthcare Cancer Care Services
Claim this profileBillings, Montana 59102
Global Leader in Breast Cancer
Global Leader in Lung Cancer
Conducts research for Lymphoma
Conducts research for Cancer
Conducts research for Breast cancer
352 reported clinical trials
9 medical researchers
Summary
St. Vincent Healthcare Cancer Care Services is a medical facility located in Billings, Montana. This center is recognized for care of Breast Cancer, Lung Cancer, Lymphoma, Cancer, Breast cancer and other specialties. St. Vincent Healthcare Cancer Care Services is involved with conducting 352 clinical trials across 412 conditions. There are 9 research doctors associated with this hospital, such as Nicholas DiBella, Patrick Cobb, MD, Benjamin J. George, and Marwan Massouh.Area of expertise
1Breast Cancer
Global LeaderHER2 negative
ER positive
Stage IV
2Lung Cancer
Global LeaderStage IV
Stage III
Stage II
Top PIs
Nicholas DiBellaRocky Mountain Cancer Centers-Boulder6 years of reported clinical research
Expert in Breast Cancer
Expert in Lung Cancer
103 reported clinical trials
193 drugs studied
Patrick Cobb, MDSt. Vincent Frontier Cancer Center6 years of reported clinical research
Studies Breast Cancer
Studies Non-Small Cell Lung Cancer
24 reported clinical trials
48 drugs studied
Benjamin J. GeorgeSCL Health Good Samaritan Medical Center Cancer Centers of Colorado6 years of reported clinical research
Studies Stomach Cancer
Studies Esophageal Cancer
12 reported clinical trials
48 drugs studied
Marwan MassouhSaint James Community Hospital and Cancer Treatment Center8 years of reported clinical research
Studies Lung Cancer
Studies Non-Small Cell Lung Cancer
11 reported clinical trials
35 drugs studied
Clinical Trials running at St. Vincent Healthcare Cancer Care Services
Lung Cancer
Ovarian Cancer
Uterine Cancer
Esophageal cancer
Breast Cancer
Non-Small Cell Lung Cancer
Breast cancer
Endometrial Adenocarcinoma
Esophageal Cancer
Stomach Cancer
Durvalumab
for Lung Cancer
This phase III trial compares durvalumab to the usual approach (patient observation) after surgery for the treatment of patients with early-stage non-small cell lung cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. The usual approach for patients who are not in a study is to closely watch a patient's condition after surgery and to have regular visits with their doctor to watch for signs of the cancer coming back. Usually, patients do not receive further treatment unless the cancer returns. This study will help determine whether this different approach with durvalumab is better, the same, or worse than the usual approach of observation. Giving durvalumab may help patients live longer and prevent early-stage non-small cell lung cancer from coming back as compared to the usual approach.
Recruiting2 awards Phase 38 criteria
Immunotherapy + Chemotherapy
for Non-Small Cell Lung Cancer
This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small cell lung cancer.
Recruiting2 awards Phase 327 criteria
Ceralasertib + Durvalumab
for Non-Small Cell Lung Cancer
This phase III trial compares the effect of adding AZD6738 to durvalumab versus durvalumab alone to increase time without cancer in patients with non-small cell lung cancer, following treatment with chemotherapy and surgery. AZD6738 may stop the growth of tumor cells and may kill them by blocking some of the enzymes needed for cell growth. Durvalumab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Adding AZD6738 to durvalumab may increase time without cancer in patients with non-small cell lung cancer, following treatment with chemotherapy and surgery.
Recruiting2 awards Phase 310 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at St. Vincent Healthcare Cancer Care Services?
St. Vincent Healthcare Cancer Care Services is a medical facility located in Billings, Montana. This center is recognized for care of Breast Cancer, Lung Cancer, Lymphoma, Cancer, Breast cancer and other specialties. St. Vincent Healthcare Cancer Care Services is involved with conducting 352 clinical trials across 412 conditions. There are 9 research doctors associated with this hospital, such as Nicholas DiBella, Patrick Cobb, MD, Benjamin J. George, and Marwan Massouh.
Where is St. Vincent Healthcare Cancer Care Services located?
**St. Vincent Healthcare Cancer Care Services**
- **Location:** 1315 Golden Valley Circle, Billings, MT 59102, east of the Peter Yegen Golf Course.
- **Services Offered:** Comprehensive cancer care encompassing treatments for blood, breast, head and neck, lung, pediatric, radiation oncology, and skin cancers.
Who should I call to ask about financial aid or insurance network?
For financial assistance at St. Vincent Healthcare Cancer Care Services, please contact customer service at 877-202-0356. For insurance-related inquiries, reach out to the general customer service line. It is advisable to contact the hospital directly for accurate and current insurance information.
What insurance does St. Vincent Healthcare Cancer Care Services accept?
St. Vincent Healthcare Cancer Care Services accepts a variety of insurance plans, including Medicare Advantage. Accepted health plans include those underwritten or supported by Aetna Healthcare, AMCO PPO, Arkansas Blue Cross and Blue Shield, Arkansas Municipal League, CIGNA, Coventry / First Health PPO, Humana, Mercy Health Plans, MultiPlan, PPO Plus, QualChoice, and United Healthcare. It's important to verify participation with your specific health plan by contacting them directly or checking their online provider directory.
What awards or recognition has St. Vincent Healthcare Cancer Care Services received?
**St. Vincent Healthcare Cancer Care Services, Billings, Montana**
- Recognized by the National Cancer Institute as a comprehensive or clinical cancer center.
- Accredited by the Foundation for the Accreditation of Cellular Therapy (FACT).
- Offers the Eva Project, providing free mammograms to uninsured or under-insured women over 40, funded by Eva, the St. Vincent Healthcare Foundation, and various events, sponsors, and donors.
- Recently launched a partnership to introduce advanced gynecologic cancer treatments.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.